BioCentury
ARTICLE | Clinical News

Vidac reports Phase IIa data for VDA-1102 in actinic keratosis

November 10, 2017 9:17 PM UTC

Vidac Pharma Ltd. (Jerusalem, Israel) said 10% VDA-1102 ointment missed the primary endpoint of reducing the mean number of actinic keratosis (AK) lesions on the face or scalp combined from baseline to day 56 vs. placebo in a Phase IIa trial to treat AK (32.1% vs. 27.8%, p=not significant). The primary endpoint was specific to the 10% dose of VDA-1102.

Vidac said 10% VDA-1102 did significantly reduce the mean number of AK lesions on the face from baseline to day 56 vs. placebo (39% vs. 29%, p=0.023) and significantly reduced the mean number of grade 2/3 lesions on the face (59.9% vs. 19.9%, p=0.0004) and on the face and scalp combined (53.1% vs. 25.9%, p=0.029) vs. placebo. VDA-1102 was well tolerated...